Circulate Health lands strategic seed funding from Scrum Ventures

Circulate Health, a California-based innovator in precision Therapeutic Plasma Exchange (TPE) and microplastics remediation, today announced a strategic seed investment from Scrum Ventures. The seven-figure funding signals robust appetite among early-stage health‑tech backers for scalable, patient-centric platforms that address complex inflammatory and aging pathways. Circulate Health’s approach combines advanced TPE techniques with microplastics-focused strategies to reduce circulating pollutants and improve vascular health.

The capital infusion is poised to accelerate R&D and clinical program expansion while speeding the path to market for Circulate’s platform. Management emphasized the funds will support ongoing research, regulatory planning, and readiness for broader clinical deployment as the company scales its operations across centers of excellence.

From a market perspective, seed investments in transformative health technology continue to rise, with investors showing preference for platforms that can demonstrate measurable health outcomes and scalable delivery. The evolving field of longevity and preventive medicine, coupled with advancements in plasma exchange and biomarker analytics, has drawn renewed interest from seed and early‑stage funds seeking to back next‑generation therapies that could redefine chronic disease management.

Brad Younggren, CEO & Co‑Founder of Circulate Health, commented, “We’re entering an era where precision TPE can become a cornerstone of preventive and therapeutic care. Partnering with Scrum Ventures gives us the resources to push ahead with our research and speed the clinical translation of our platform.”

Michael Proman, Partner at Scrum Ventures, added, “Circulate is at the nexus of science-led health tech and patient‑centered care. Their scalable TPE platform has the potential to redefine how we address inflammatory processes and age‑related conditions, making this collaboration particularly compelling for Scrum’s portfolio.”

Circulate Health’s broader investor base also includes Khosla Ventures, underscoring continued confidence in the company’s mission to improve human healthspan through plasma exchange innovations. The latest funding round reinforces a trend where experienced health‑tech backers back platform stories that offer a clear path to clinical impact and mass adoption. As Circulate advances, market watchers will monitor regulatory milestones, center expansions, and value delivery to patients and healthcare systems alike.